Rituxan Sales Of $37.7 Mil. Offset Declines In Other Genentech Products
Sales of Genentech/Idec's Rituxan have reached $43.2 mil. since launch, with sales of $5.5 mil. in the fourth quarter of 1997 and $37.7 mil. in the first quarter of 1998. FDA approved Rituxan Nov. 26.
You may also be interested in...
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011